SCHEMBL18368348

SCHEMBL18368348

CC(C)c1cccc2c1C=CCC2=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
GABRA1 P14867 3/20 0.36
FAAH O00519 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRB2 P47870 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
GABRB1 P18505 1/20 0.36
PTGS1 P23219 1/20 0.36
SLC6A2 P23975 1/20 0.36
HTR2C P28335 1/20 0.36
GABRA5 P31644 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17577745 0.78 ACHE (0.37) DPP4CA1CA2LMNACYP1A2
SCHEMBL28929035 0.74 PIM1 (0.38) CA1CA2CA9
SCHEMBL1842983 0.74 MAPT (0.41) CA1CA2LMNACYP1A2CYP3A4
SCHEMBL6909918 0.73 GABRA1 (0.41) GABRA1FAAHCA1CA2GABRG2
SCHEMBL13930824 0.72 ALDH1A1 (0.32)
SCHEMBL17571965 0.72 MEN1 (0.31) PTGS1KMT2A
SCHEMBL24759701 0.70 CA1 (0.38) DPP4NR1H2NR1H3GABRA1FAAH
SCHEMBL15070846 0.70
SCHEMBL5344889 0.70 CA1 (0.35) DPP4NR1H2NR1H3GABRA1FAAH
SCHEMBL1025203 0.69 GABRA1 (0.41) DPP4NR1H2NR1H3GABRA1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827662-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2023-11-28 US disclosed
US-9878995-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2018-01-30 US disclosed
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-06-01 US disclosed
US-20170008905-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS DPP4 3764/4885NR1H2 2223/4885NR1H3 1800/4885
US-20170008905-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS DPP4 3764/4885NR1H2 2223/4885NR1H3 1800/4885
US-11827662-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS DPP4 3764/4885NR1H2 2223/4885NR1H3 1800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.